Investor Presentaiton slide image

Investor Presentaiton

US Mesh litigation - Overview of financial impact P&L - overview of special items related to the Mesh litigation Balance Assets Restricted cash, DKKbn Cash flow Actual/Expected cash flow, DKKbn Actual cash flow ☐ Expected cash flow 13/14- 17/18 18/19 19/20 20/21 21/22 YTD 22/23 0.5 0.5 EBIT (before special items) 5,556 5,854 6,355 6,910 3,445 Special items (Mesh) -4,750 -400 -200 -300 Other special items* -171 -33 0.1 0.0 0.0 EBIT 5,156 5,854 6,155 6,439 3,412 0.0 0.0 0.0 14/15 15/16 16/17 17/18 18/19 19/20 20/21 21/22 YTD 22/23 0.0 0.5 0.3 Liabilities EBIT % (before special items) 31 32 33 31 28 Total liability, DKKbn EBIT % 29 32 32 32 29 28 Other payables Provision 0.7 • A total of DKK 6,150 million (DKK 5,650 million net of insurance coverage) has been provisioned and is considered sufficient • Currently around 99% of known cases against Coloplast have been resolved 2.4 3.3 * DKK 171 million in special items related to the Atos Medical acquisition (transaction and integration costs) in FY 2021/22. DKK 33 million in special items related to integration costs for the Atos Medical acquisition in H1 2022/23. 63 1.2 0.1 0.1 0.3 1.1 0.4 0.3 0.5 0.1 0.3 0.2 0.2 0.0 0.1 14/15 15/16 16/17 17/18 18/19 19/20 20/21 21/22 YTD 22/23 1.8 1.6 22/23 & beyond 0.3 0.5 0.4 0.2 0.2 0.2 0.1 13/14 14/15 15/16 16/17 17/18 18/19 19/20 20/21 21/22 22/23 • Insurance coverage of DKK 500m received in 2013/14 and 2014/15 Coloplast
View entire presentation